New study tests if tumor genes and organoids can outsmart pancreatic cancer

NCT ID NCT06615830

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study will enroll 185 people with metastatic pancreatic cancer to see if analyzing tumor genes and lab-grown organoids can predict which standard chemotherapy regimens work best. Researchers will compare predicted drug sensitivity to actual patient outcomes. The tests are experimental and not used to guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Transcriptome-based OncoTreat/OncoTarget testing and patient-derived organoids
What this could lead to
If successful, this could show that combining genetic analysis with organoid testing helps predict effective treatments for pancreatic cancer, paving the way for more personalized therapy.
What could go wrong
This is an observational study, not a treatment trial. The tests are experimental and not yet proven to improve outcomes. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.